Clinical Trials Logo

Clinical Trial Summary

This protocol provides ongoing access to triheptanoin for patients who did complete an initial pilot protocol, and provides the opportunity to collect long-term safety data from patients treated with triheptanoin.


Clinical Trial Description

Only patients who completed the initial pilot study were eligible. The study is ongoing with these patients only. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02018302
Study type Expanded Access
Source University of Texas Southwestern Medical Center
Contact
Status No longer available
Phase

See also
  Status Clinical Trial Phase
Terminated NCT02599961 - Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS) Phase 2
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT05085704 - Brain Metabolism Observed at 7 Tesla
Withdrawn NCT03202108 - Evaluation of Krio in Children and Adults With Epilepsy N/A
Active, not recruiting NCT04137692 - Red Blood Cell Exchange Transfusion as a Novel Treatment for GLUT1 Deficiency Syndrome N/A
Completed NCT03041363 - Treatment Development of Triheptanoin (G1D) Phase 1
Completed NCT02018315 - Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) Phase 1
Completed NCT04399954 - Evaluation of Ketoflo N/A
Withdrawn NCT02021526 - Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D) Phase 1/Phase 2
Recruiting NCT02013583 - The Glucose Transporter Type I Deficiency (G1D) Registry
Completed NCT02915211 - Evaluation of Keyo in Children With Epilepsy N/A
Active, not recruiting NCT02000960 - Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome Phase 2
Active, not recruiting NCT03181399 - Diet Treatment Glucose Transporter Type 1 Deficiency (G1D) Phase 2